

Supplementary Table 1. Chemical Inhibitors to cell signaling pathways

Inhibitor	Signaling Pathway	Concentration ^a
U0126	MEK1/2	5 M
Wortmannin	PI3K	200 nM
Parthenolide	NF B	10 M
SP600125	JNK	30 M
SB203580	p38 MAPK	10 M
AG490	JAK/STAT	20 M
-4-Dibromoacetophenone	GSK3	10 M
(Z,E)-5-(4-Ethylbenzylidene)-2-thioxothiazolidin-4-one	c-MYC/MAX	15 M

^a Concentrations used for our inhibitor treatments in all experiments, unless noted differently.

Supplementary Table 2. Kallikrein primer sequences used for RT-PCR

Kallikrein		Sequence	predicted size (bp)
<i>PSA (hK3)</i>	forward	5' CCCACTGCATCAGGAACAAAAGCG 3'	600
	reverse	5' GGTGCTCAGGGGTGGCCAC 3'	
<i>KLK10</i>	forward	5' GGAAACAAGCCACTGTGGGC 3'	470
	reverse	5' GAGGATGCCTTGGAGGGTCTC 3'	
<i>KLK11</i>	forward	5' CTCGGCAACAGGGCTTGTAGGG 3'	460
	reverse	5' GCATCGCAAGGTGTGAGGCAGG 3'	
<i>KLK13</i>	forward	5' GGAGAAGCCCCACCCACCTG 3'	440
	reverse	5' CACGGATCCACAGGACGTATCTTG 3'	
<i>KLK14</i>	forward	5' CACTGCGGCCGCCCCGATC 3'	485
	reverse	5' GGCAGGGCGCAGCGCTCC 3'	
<i>-actin</i>	forward	5' ATCTGGCACCACCTTCTA 3'	850
	reverse	5' CGTCATACTCCTGCTTGCTG 3'	

Supplementary Table 3. ChIP *KLK* Primers

KLK		Sequence
PSA		
I	Forward	5' CCTGCTGGCACCCAGAGGC 3'
	Reverse	5' GAATGCTAGGGAACTTTGGGAG 3'
II	Forward	5' GTAGAGACAGAGTTTCACCATGTTG 3'
	Reverse	5' GATTACAGGCGTCAGCCACCGC 3'
III	Forward	5' GGAGTGCAAAGGATCTAGGCACG 3'
	Reverse	3' GAGACAGAAAAGAGCCCAGCTCC 3'
KLK10		
I	Forward	5' CTGGCTAACACCATGCTCAACG 3'
	Reverse	5' GGGTCTAGCACATAGTAAGCACTCAG 3'
II	Forward	5' GCTGCTGATGGCGCAACTCTG 3'
	Reverse	5' ACCACGGTGAAATCCCATCTCTAC 3'
III	Forward	5' TTCGTAGAGACAGAGGTCTCAGTATTG 3'
	Reverse	5' GTGAGACAGAGGAGTTACATTTCTGG 3'
KLK11		
I	Forward	5' CCCAGCTACTTGGGAAGCTGAGG 3'
	Reverse	5' GGGTCCACTTGGAAAGAGCAGACTG 3'
II	Forward	5' GTGTGGGGGAGTCCTTCAAGGTC 3'
	Reverse	5' GGGGTTTCACTATGTTGACCAGGC 3'